RxDoctor Payments Data

Michael Annabi, MD

Internal Medicine · El Paso, TXNPI 1962484378

Payments from drug & device makers

$188,178in general payments, 2019–2025

Across 989 payments — averaging $190.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$99K
  • Boehringer Ingelheim$31K
  • AstraZeneca$22K
  • Sanofi-aventis U.S. LLC$15K
  • Lilly USA, LLC$12K
  • Pfizer$994
  • plus $7K from 50 others

What the payments were for

  • Consulting fees$4,2902%
  • Speaking & faculty fees$161,36086%
  • Travel & lodging$7,3374%
  • Food & beverage$15,1658%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$188,178 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$437,748
Medicare patients
851
Services billed
5,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide402$510,725
JardianceEmpagliflozin262$326,634
FarxigaDapagliflozin Propanediol239$284,155
MounjaroTirzepatide137$164,971
EliquisApixaban95$94,865
TrulicityDulaglutide61$76,827
KerendiaFinerenone40$52,329
XifaxanRifaximin14$51,755
Bydureon BciseExenatide Microspheres30$45,604
RybelsusSemaglutide24$42,123
XareltoRivaroxaban36$36,203
LinzessLinaclotide28$31,966
EntrestoSacubitril/Valsartan30$31,244
TymlosAbaloparatide11$29,023
Tresiba Flextouch U-100Insulin Degludec57$27,728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$99,190$552,848426 claims
Boehringer IngelheimJardiance, Combivent Respimat$31,294$332,478274 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$22,419$316,283280 claims
Lilly USA, LLCMounjaro, Trulicity$11,988$241,799198 claims
PfizerEliquis, Nurtec Odt$994$119,737106 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$349$60,34925 claims
BayerKerendia$486$52,32940 claims
Johnson & JohnsonXarelto$800$36,20336 claims
AbbVieLinzess$417$31,96628 claims
NovartisEntresto$321$31,24430 claims
Radius Health, Inc.Tymlos$92$29,02311 claims
GSKTrelegy Ellipta$123$22,48317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →